AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37846935 — intervention group
Group type: COMPARATOR
Intervention: Invasive Mechanical Ventilation (IMV)
Number of subjects: 696
Study 37847068 — intervention group
Group type: EXPERIMENTAL
Intervention: EXP (mentally fatiguing task; individualized 60-min Stroop task)
Number of subjects: 14
Study 37847068 — intervention group
Group type: COMPARATOR
Intervention: CON (control task; documentary)
Number of subjects: 14
Study 37847109 — intervention group
Group type: EXPERIMENTAL
Intervention: FLACS diabetic
Number of subjects: 152
Study 37847109 — intervention group
Group type: COMPARATOR
Intervention: MCS diabetic
Number of subjects: 152
Study 37847109 — intervention group
Group type: EXPERIMENTAL
Intervention: FLACS
Number of subjects: 152
Study 37847127 — intervention group
Group type: EXPERIMENTAL
Intervention: Premium monovision (Panoptix IOL in recessive eye and Vivity IOL in dominant eye)
Number of subjects: 90
Study 37847127 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral trifocal (Panoptix IOL bilaterally)
Number of subjects: 90
Study 37847127 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral xEDOF (Vivity IOL bilaterally)
Number of subjects: 90
Study 37847131 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT) prior to endovascular thrombectomy (EVT)
Number of subjects: 1408
Study 37847131 — intervention group
Group type: COMPARATOR
Intervention: Endovascular thrombectomy (EVT) without intravenous thrombolysis (IVT)
Number of subjects: 1408
Study 37847138 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D CE US 4-6 weeks after TACE
Number of subjects: 132
Study 37847138 — intervention group
Group type: COMPARATOR
Intervention: CE MRI or CT 4-6 weeks after TACE
Number of subjects: 132
Study 37847273 — intervention group
Group type: EXPERIMENTAL
Intervention: Million Hearts Model intervention
Number of subjects: 342
Study 37847273 — intervention group
Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 342
Study 37847273 — intervention group
Group type: COMPARATOR
Intervention: Medicare spending for CVD events
Number of subjects: 342
Study 37847273 — intervention group
Group type: COMPARATOR
Intervention: Overall Medicare spending including model payments
Number of subjects: 342
Study 37847288 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemp supplementation (60 g/d containing 40 g protein and 9 g oil)
Number of subjects: 34
Study 37847288 — intervention group
Group type: COMPARATOR
Intervention: Soy supplementation (60 g/d matched for protein and calories)
Number of subjects: 34
Study 37847288 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemp supplementation
Number of subjects: 34
Study 37847317 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (4 g of omega-3 acid ethyl esters, Lovaza)
Number of subjects: 60
Study 37847317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 37847317 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 60
Study 37847423 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of pharmacists in deprescribing interventions
Number of subjects: 0
Study 37847423 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprescribing interventions
Number of subjects: 0
Study 37847423 — intervention group
Group type: COMPARATOR
Intervention: Emotional barriers identified by clinicians
Number of subjects: 0
Study 37847423 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional facilitators identified by pharmacists
Number of subjects: 0
Study 37847442 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 4385
Study 37847442 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 4385
Study 37847454 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet-CPAP
Number of subjects: 28
Study 37847454 — intervention group
Group type: COMPARATOR
Intervention: Non-rebreather mask (NRB)
Number of subjects: 28
Study 37847454 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen masks with higher FiO
Number of subjects: 28
Study 37847518 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-µg mRNA-1273 (Moderna)
Number of subjects: 273
Study 37847518 — intervention group
Group type: COMPARATOR
Intervention: 30-µg BNT162b2 (Pfizer-BioNTech)
Number of subjects: 273
Study 37847542 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Meditation (VRM)
Number of subjects: 13
Study 37847548 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepsychiatry (n=240)
Number of subjects: 480
Study 37847548 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (face-to-face evaluation, n=240)
Number of subjects: 480
Study 37847688 — intervention group
Group type: EXPERIMENTAL
Intervention: nintedanib 150 mg BID plus weekly docetaxel (35 mg/m2)
Number of subjects: 14
Study 37847688 — intervention group
Group type: EXPERIMENTAL
Intervention: nintedanib 200 mg BID plus weekly docetaxel (35 mg/m2)
Number of subjects: 14
Study 37847695 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Review with Follow-up (MRF) service
Number of subjects: 162
Study 37847761 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (mean dose of 304 mg/m²)
Number of subjects: 25
Study 37847761 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (sex- and age-matched)
Number of subjects: 25
Study 37847768 — intervention group
Group type: EXPERIMENTAL
Intervention: FlowTriever mechanical thrombectomy
Number of subjects: 114
Study 37847768 — intervention group
Group type: COMPARATOR
Intervention: Other contemporary therapies (primarily systemic thrombolysis and anticoagulation)
Number of subjects: 114
Study 37847947 — intervention group
Group type: COMPARATOR
Intervention: High-intensity percutaneous electrolysis (three pulses of 3 mA, 3s)
Number of subjects: 46
Study 37847947 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity percutaneous electrolysis (0.3 mA, 90s)
Number of subjects: 46
Study 37847947 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham (without electrical current)
Number of subjects: 46
Study 37848174 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 1107
Study 37848174 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (pre-TAVR VKA users)
Number of subjects: 1107
Study 37848174 — intervention group
Group type: COMPARATOR
Intervention: VKA
Number of subjects: 1107
Study 37848259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosibelimab 800 mg intravenously every 2 weeks
Number of subjects: 78
Study 37848292 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital emergency manual (EM) used by resuscitation teams after a management plan has been derived ('Do-Confirm').
Number of subjects: 50
Study 37848292 — intervention group
Group type: EXPERIMENTAL
Intervention: Team's subjective evaluation of the EM's value on a Likert scale of 1-6.
Number of subjects: 50
Study 37848295 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measures (PROMs) and clinical examinations at 0, 3, 6, and 12 months
Number of subjects: 500
Study 37848295 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive evaluation, 6-minute walk test (6MWT), and hand grip strength measurement at baseline
Number of subjects: 500
Study 37848297 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrvinium pamoate (PP) at 5 mg/kg orally for 3 days prior to surgery.
Number of subjects: 3
Study 37848297 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrvinium pamoate (PP) at 10 mg/kg orally for 3 days prior to surgery (if tolerated).
Number of subjects: 3
Study 37848297 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrvinium pamoate (PP) at 20 mg/kg orally for 3 days prior to surgery (if tolerated).
Number of subjects: 3
Study 37848297 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrvinium pamoate (PP)
Number of subjects: 3
Study 37848299 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-child yoga intervention in addition to standard clinical care
Number of subjects: 24
Study 37848299 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care alone
Number of subjects: 24
Study 37848307 — intervention group
Group type: EXPERIMENTAL
Intervention: Upgraded 6-month intensive cardiac rehabilitation programme combining nutritional counselling, Mediterranean diet, and exercise training.
Number of subjects: 36
Study 37848307 — intervention group
Group type: EXPERIMENTAL
Intervention: 8:16 hour time-restricting eating (TRE) at least 5 days per week added to the existing interventions in Phase 2.
Number of subjects: 36
Study 37848336 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry electrode EEG (8 electrodes) performed by ambulance personnel
Number of subjects: 311
Study 37848634 — intervention group
Group type: EXPERIMENTAL
Intervention: CS1-BCMA CAR-T infusion
Number of subjects: 16
Study 37848651 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated baseline levels of high-sensitivity C-reactive protein (hs-CRP)
Number of subjects: 585
Study 37848651 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP levels
Number of subjects: 585
Study 37848651 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptoms assessed with CES-D
Number of subjects: 585
Study 37848690 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation intervention (home-based program)
Number of subjects: 133
Study 37848768 — intervention group
Group type: EXPERIMENTAL
Intervention: simethicone (S)
Number of subjects: 800
Study 37848768 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 800
Study 37848768 — intervention group
Group type: EXPERIMENTAL
Intervention: simethicone and N-acetyl cysteine (S + NAC)
Number of subjects: 800
Study 37848768 — intervention group
Group type: COMPARATOR
Intervention: water (Control)
Number of subjects: 800
Study 37848768 — intervention group
Group type: EXPERIMENTAL
Intervention: Late endoscopy (> 20-30 minutes)
Number of subjects: 800
Study 37848768 — intervention group
Group type: EXPERIMENTAL
Intervention: Early endoscopy (10-20 minutes)
Number of subjects: 800
Study 37848857 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 min of mindfulness-based real-time fMRI neurofeedback (mbNF)
Number of subjects: 90
Study 37848857 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min of mindfulness-based real-time fMRI neurofeedback (mbNF)
Number of subjects: 90
Study 37848857 — intervention group
Group type: EXPERIMENTAL
Intervention: mindfulness-based real-time fMRI neurofeedback (mbNF)
Number of subjects: 90
Study 37848867 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term antiretroviral therapy (ART)
Number of subjects: 0
Study 37848867 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural roadmap for study design
Number of subjects: 0
Study 37848887 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg immediate release methylphenidate (IR-MPH)
Number of subjects: 40
Study 37848887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 37848908 — intervention group
Group type: EXPERIMENTAL
Intervention: MyoCare ophthalmic lenses
Number of subjects: 300
Study 37848908 — intervention group
Group type: COMPARATOR
Intervention: Clearview ophthalmic lenses
Number of subjects: 300
Study 37848916 — intervention group
Group type: EXPERIMENTAL
Intervention: ARCHES intervention
Number of subjects: 0
Study 37848929 — intervention group
Group type: EXPERIMENTAL
Intervention: Drivingly Program (comprehensive parent-teen intervention)
Number of subjects: 100
Study 37848929 — intervention group
Group type: COMPARATOR
Intervention: Usual practice control group
Number of subjects: 100
Study 37848969 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cluster-set resistance training program, 8 weeks, 3 days per week, with supervised sessions and virtual supervision
Number of subjects: 14
Study 37848969 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cluster-set resistance training program
Number of subjects: 14
Study 37848970 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim methadone without routine counseling
Number of subjects: 16
Study 37848970 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth for counseling
Number of subjects: 16
Study 37848970 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote counseling access
Number of subjects: 16
Study 37848970 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake through telehealth
Number of subjects: 16
Study 37849000 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (ta-VNS) targeting the cymba conchae of the external left ear, 5 min duration once daily for 2 weeks, followed by crossover to sham stimulation for 2 weeks, then ta-VNS 5 min duration twice daily until week 16.
Number of subjects: 22
Study 37849000 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (ta-VNS)
Number of subjects: 22
Study 37849000 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (ta-VNS) in UC subjects
Number of subjects: 22
Study 37849000 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (ta-VNS) in CD subjects
Number of subjects: 22
Study 37849504 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin as adjunctive therapy
Number of subjects: 247
Study 37849628 — intervention group
Group type: EXPERIMENTAL
Intervention: Zagotenemab 70 mg
Number of subjects: 22
Study 37849628 — intervention group
Group type: EXPERIMENTAL
Intervention: Zagotenemab 210 mg
Number of subjects: 22
Study 37849628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 37849628 — intervention group
Group type: EXPERIMENTAL
Intervention: Zagotenemab (both doses)
Number of subjects: 22
Study 37849833 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive neuromodulation-induced cortical prehabilitation (NICP) protocol, involving 10 to 20 daily sessions of neuromodulation coupled with intensive task training.
Number of subjects: 0
Study 37849833 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive NICP protocol
Number of subjects: 0
Study 37850041 — intervention group
Group type: EXPERIMENTAL
Intervention: VIBe scale (Validated Intraoperative Bleeding Scale)
Number of subjects: 259
Study 37850041 — intervention group
Group type: EXPERIMENTAL
Intervention: VIBe scale
Number of subjects: 259
Study 37850105 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable biosensor monitoring
Number of subjects: 9
Study 37850105 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized temporal models
Number of subjects: 9
Study 37850105 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest (RF) and Mixed-Effect Random Forest (MERF) models
Number of subjects: 9
Study 37850197 — intervention group
Group type: EXPERIMENTAL
Intervention: App-delivered cognitive-behavioral therapy for insomnia (CBT-I) adjunct to inpatient multimodal rehabilitation
Number of subjects: 0
Study 37850197 — intervention group
Group type: COMPARATOR
Intervention: Inpatient multimodal rehabilitation (usual care)
Number of subjects: 0
Study 37850330 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine and ketamine infusions
Number of subjects: 319
Study 37850359 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Conditioning (RIC)
Number of subjects: 1773
Study 37850359 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 1773
Study 37850379 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran sodium 300 mg (equivalent to 284 mg of inclisiran)
Number of subjects: 56
Study 37850379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 37850383 — intervention group
Group type: EXPERIMENTAL
Intervention: Early routine left ventricular unloading with transseptal left atrial cannulation within 12 hours after randomization (n=58)
Number of subjects: 116
Study 37850383 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach permitting rescue transseptal left atrial cannulation (n=58)
Number of subjects: 116
Study 37850681 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-seizure medications
Number of subjects: 20
Study 37850681 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-EEG
Number of subjects: 20
Study 37850681 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up EEG
Number of subjects: 20
Study 37850816 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVST
Number of subjects: 450
Study 37850816 — intervention group
Group type: EXPERIMENTAL
Intervention: HIVST + mHealth
Number of subjects: 450
Study 37850816 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 450
Study 37850922 — intervention group
Group type: EXPERIMENTAL
Intervention: Livestock feed and nutritional counseling
Number of subjects: 1734
Study 37850922 — intervention group
Group type: EXPERIMENTAL
Intervention: Livestock feed only
Number of subjects: 1734
Study 37850922 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1734
Study 37850941 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubeless Automated Insulin Delivery System
Number of subjects: 0
Study 37851072 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab/utomilumab/avelumab (cohort 1)
Number of subjects: 24
Study 37851072 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab/ivuxolimab/utomilumab (cohort 2)
Number of subjects: 24
Study 37851095 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-hyaluronate mouthwash
Number of subjects: 32
Study 37851095 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 32
Study 37851128 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Sirtuin6
Number of subjects: 40
Study 37851128 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva Lipoxin A4
Number of subjects: 40
Study 37851128 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical periodontal parameters
Number of subjects: 40
Study 37851143 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosaprepitant combined with tropisetron and dexamethasone
Number of subjects: 103
Study 37851143 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fosaprepitant)
Number of subjects: 103
Study 37851284 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) oxygen therapy for 1 hour
Number of subjects: 22
Study 37851284 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen therapy for 1 hour
Number of subjects: 22
Study 37851297 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotatercept plus background therapy (BGT)
Number of subjects: 0
Study 37851297 — intervention group
Group type: COMPARATOR
Intervention: BGT alone
Number of subjects: 0
Study 37851321 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Number of subjects: 0
Study 37851321 — intervention group
Group type: COMPARATOR
Intervention: Real-world data (RWD) sources
Number of subjects: 0
Study 37851321 — intervention group
Group type: COMPARATOR
Intervention: Frequentist estimation
Number of subjects: 0
Study 37851336 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg oral eliapixant twice daily
Number of subjects: 135
Study 37851336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 37851412 — intervention group
Group type: EXPERIMENTAL
Intervention: HZ/su vaccine (Shingrix)
Number of subjects: 82
Study 37851412 — intervention group
Group type: EXPERIMENTAL
Intervention: HZ/su vaccine (Shingrix) in patients receiving JAKi + methotrexate
Number of subjects: 82
Study 37851446 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine buprenorphine initiation
Number of subjects: 41626
Study 37851446 — intervention group
Group type: COMPARATOR
Intervention: Nontelemedicine buprenorphine initiation
Number of subjects: 41626
Study 37851488 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training performed using a cycle ergometer, 3 times per week for 4 weeks.
Number of subjects: 24
Study 37851488 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group).
Number of subjects: 24
Study 37851498 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital model of care (intervention)
Number of subjects: 198
Study 37851498 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 198
Study 37851500 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth intervention
Number of subjects: 10
Study 37851500 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth tools
Number of subjects: 10
Study 37851500 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of eHealth solutions
Number of subjects: 10
Study 37851500 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication channels
Number of subjects: 10
Study 37851500 — intervention group
Group type: EXPERIMENTAL
Intervention: Research study and pandemic situation
Number of subjects: 10
Study 37851566 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg (DTG)
Number of subjects: 613
Study 37851566 — intervention group
Group type: COMPARATOR
Intervention: Low-dose Efavirenz (EFV400)
Number of subjects: 613
Study 37851566 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 613
Study 37851562 — intervention group
Group type: EXPERIMENTAL
Intervention: faricimab 6.0 mg Q8W
Number of subjects: 144
Study 37851562 — intervention group
Group type: EXPERIMENTAL
Intervention: faricimab per personalized treatment interval (PTI)
Number of subjects: 144
Study 37851562 — intervention group
Group type: COMPARATOR
Intervention: aflibercept 2.0 mg Q8W
Number of subjects: 144
Study 37851562 — intervention group
Group type: EXPERIMENTAL
Intervention: faricimab PTI
Number of subjects: 144
Study 37851608 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose rituximab plus glucocorticoid (methylprednisolone 0.8 mg/kg per day for the first 3 weeks and then tapered)
Number of subjects: 63
Study 37851608 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide plus glucocorticoid (methylprednisolone 0.8 mg/kg per day for the first 3 weeks and then tapered)
Number of subjects: 63
Study 37851663 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (12-week treatment)
Number of subjects: 81
Study 37851732 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-3L questionnaire at 12 months
Number of subjects: 1047
Study 37851732 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-3L questionnaire at 3, 6, and 9 months
Number of subjects: 1047
Study 37851732 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 1047
Study 37851732 — intervention group
Group type: EXPERIMENTAL
Intervention: Major cardiovascular events
Number of subjects: 1047